애노비스 바이오(ANVS)는 NYSE에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.85 (+3.35%), 시가총액 $0.07B, 52주 범위 $1.59 ~ $5.10.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
애노비스 바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
애노비스 바이오의 현재 주가는 $1.85 (+3.35%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
애노비스 바이오의 시가총액은 약 $0.07B입니다.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to tr